EF Hutton Initiates Coverage On One Liberty Props with Buy Rating, Announces Price Target of $30
EF Hutton analyst Gaurav Mehta initiates coverage on One Liberty Props (NYSE:OLP) with a Buy rating and announces Price Target of $30.
SVB Leerink Initiates Coverage On MoonLake with Outperform Rating, Announces Price Target of $17
SVB Leerink analyst Thomas Smith initiates coverage on MoonLake (NASDAQ:MLTX) with a Outperform rating and announces Price Target of $17.
Morgan Stanley Initiates Coverage On Kinetik Holdings with Equal-Weight Rating, Announces Price Target of $46
Morgan Stanley analyst Robert Kad initiates coverage on Kinetik Holdings (NASDAQ:KNTK) with a Equal-Weight rating and announces Price Target of $46.
Piper Sandler Initiates Coverage On NICE with Neutral Rating, Announces Price Target of $236
Piper Sandler analyst James Fish initiates coverage on NICE (NASDAQ:NICE) with a Neutral rating and announces Price Target of $236.
Piper Sandler Initiates Coverage On Avidbank Holdings with Overweight Rating, Announces Price Target of $24
Piper Sandler analyst Andrew Liesch initiates coverage on Avidbank Holdings (OTC:AVBH) with a Overweight rating and announces Price Target of $24.
B. Riley Securities Initiates Coverage On Actinium Pharmaceuticals with Buy Rating, Announces Price Target of $16
B. Riley Securities analyst Yuan Zhi initiates coverage on Actinium Pharmaceuticals (AMEX:ATNM) with a Buy rating and announces Price Target of $16.
Benchmark Initiates Coverage On NOV with Hold Rating
Benchmark analyst Doug Becker initiates coverage on NOV (NYSE:NOV) with a Hold rating.
Credit Suisse Initiates Coverage On Avantor with Neutral Rating, Announces Price Target of $32
Credit Suisse analyst Dan Leonard initiates coverage on Avantor (NYSE:AVTR) with a Neutral rating and announces Price Target of $32.
Credit Suisse Initiates Coverage On Fulgent Genetics with Outperform Rating, Announces Price Target of $65
Credit Suisse analyst Dan Leonard initiates coverage on Fulgent Genetics (NASDAQ:FLGT) with a Outperform rating and announces Price Target of $65.
Credit Suisse Initiates Coverage On Guardant Health with Outperform Rating, Announces Price Target of $80
Credit Suisse analyst Dan Leonard initiates coverage on Guardant Health (NASDAQ:GH) with a Outperform rating and announces Price Target of $80.